共 50 条
- [1] RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL[J]. HAEMATOLOGICA, 2014, 99 : 131 - 132Mead, A.Clark, R.Chacko, J.Knapper, S.Yin, J.Milojkovic, D.Farquharson, M.Ali, S.Garg, M.Andrews, C.Dawson, M. KtiouetHarrison, C.
- [2] Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) : 29 - 39Mead, Adam J.Milojkovic, DraganaKnapper, StevenGarg, MamtaChacko, JosephFarquharson, MiraYin, JohnAli, SahraClark, Richard E.Andrews, ChrisDawson, Meryem KtiouetHarrison, Claire
- [3] Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence[J]. LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2259 - 2267Harrison, Claire N.Talpaz, MosheMead, Adam J.
- [4] HIGH MOLECULAR RISK MUTATIONS ARE ASSOCIATED WITH CLINICAL RESPONSE AND OUTCOME IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB[J]. HAEMATOLOGICA, 2021, 106 (10) : 84 - 85Palandri, F.Bartoletti, D.Bonifacio, M.Iurlo, A.Benevolo, G.Elli, E. M.Auteri, G.Beggiato, E.Tieghi, A.Crugnola, M.Bosi, C.Ottaviani, E.Caocci, G.Polverelli, N.Cavazzini, F.Tiribelli, M.Pugliese, N.Binotto, G.Isidori, A.Lemoli, R. M.Cilloni, D.Martino, B.Abruzzese, E.Bocchia, M.Latagliata, R.Cavo, M.Vianelli, N.Breccia, M.Palumbo, G. A.
- [5] Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study[J]. HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 285 - 290Palandri, FrancescaTiribelli, MarioBenevolo, GiuliaTieghi, AlessiaCavazzini, FrancescoBreccia, MassimoBergamaschi, MicaelaSgherza, NicolaPolverelli, NicolaCrugnola, MonicaIsidori, AlessandroBinotto, GianniHeidel, Florian H.Buccisano, FrancescoMartino, BrunoLatagliata, RobertoSpinsanti, MarcoKallenberg, LydiaPalumbo, Giuseppe AlbertoAbruzzese, ElisabettaScaffidi, LuigiCuneo, AntonioCavo, MicheleVianelli, NicolaBonifacio, Massimiliano
- [6] Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone[J]. BLOOD, 2023, 142Mead, Adam J.Harrison, Claire N.Huntly, BrianPsaila, BethanBoucher, RebeccaFox, SoniaHopkins, LouiseRogers, JosephGaskell, CharlottePatel, Amit
- [7] Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (02) : 244 - 248Pardanani, AnimeshTefferi, AyalewMasszi, TamasMishchenko, ElenaDrummond, MarkJourdan, EricVannucchi, AlessandroJurgutis, MindaugasRibrag, VincentRambaldi, AlessandroKoh, Liang PiuRose, ShelonitdaZhang, JunHarrison, Claire
- [8] Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib[J]. BLOOD, 2014, 124 (21)Zarzour, AhmadTabarroki, AliVisconte, ValeriaTaftaf, RokanaRogers, Heesun J.Ai, JingPapadantonakis, NikolaosLichtin, Alan E.Saunthararajah, YogenStein, Brady L.Tiu, Ramon V.
- [9] Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis[J]. DRUGS OF TODAY, 2020, 56 (12) : 755 - 768Schiffer, M.Kowalski, A.Zhao, J.Bewersdorf, J. P.Lewis, R. S., Jr.Zeidan, A. M.
- [10] A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)[J]. BLOOD, 2021, 138Vianelli, NicolaBenevolo, GiuliaVannucchi, AlessandroHarrison, Claire N.Loschi, MichaelAl-Ali, Haifa KathrinBonifacio, MassimilianoCervantes, FranciscoWrobel, TomaszBarosi, GiovanniKiladjian, Jean-JaquesVerstovsek, SrdanMesa, Ruben A.Rose, ShelonitdaGharpure, VishwanathHernandez, ChristopherZhang, JunPassamonti, Francesco